Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Community-acquired infections such as community-acquired pneumonia (CAP) and urinary tract infection (UTI) remain leading causes of hospitalization and death due to infections in older persons in Europe. Hospitalization often results in further disabilities and frailty for older and frail individuals, from which some may never recover. Physical activity is well-established as a cornerstone in the primary prevention and treatment of several noncommunicable diseases. However, there is currently no established rehabilitation model following a pneumonia or other infection, nor is there any evidence to support the impact of rehabilitation on the mental and physical health of older and frail individuals following a pneumonia hospitalization or other infection.
The aim of the feasibility study is to evaluate a patient-centered and individualized exercise intervention that is kick-started during hospitalization and continued for 3 months after discharge with video-supervised home-based exercise training to patients hospitalized with CAP or UTI compared to standard care with regard to safety, clinical outcomes, patients' perception, functional ability, organizational aspects, and economic aspects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Video-supervised home-based exercise training | Experimental | In-hospital exercise training: 30 min of daily one-on-one supervised exercise training using exercises from the exercise booklet "Sick but Healthy and Active". Patient-centred video-supervised home-based exercise intervention phase (weeks 0-12): 3 weekly exercise sessions (3 supervised sessions/week) over 12 weeks. Each session will last 45-50 min, consisting of 10-15 min of endurance, 20-30 min of resistance, and 5 min of balance exercises. The exercise intensity will progressively increase during the 12 weeks and be based on a target training intensity of 4-7 points on the Borg CR-10 scale. The exercise training is supplemented with weekly, individualised step-count goals that progressively increase (+5%) if previous step goals are achieved. Self-directed maintenance exercise phase (weeks 13-24): unsupervised self-directed exercise training 3 times per week for 12 weeks with phone calls, but with less frequency (see standard care below). |
|
| Standard care | No Intervention | In-hospital: Patients will receive standard of care as recommended by their healthcare personnel. Control phase (weeks 0-12): Patients are contacted biweekly by phone calls after discharge up to 12 weeks after discharge. The patients will not receive any specific recommendations regarding physical activity. Control phase (week 13-24): The patients will continuously receive phone calls, but with less frequency (i.e., 3 calls per week in week 13-16, 1 call per week in week 17-20, and 0 call per week in week 21-24). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Video-supervised home-based exercise training | Behavioral | 12 weeks of patient-centered video-supervised home-based exercise training that will be kick-started during hospitalization and continued for 12 weeks after discharge, followed by 12 weeks of self-directed maintenance exercise. |
| Measure | Description | Time Frame |
|---|---|---|
| Re-hospitalization (infection-related and all-cause) | Report of the total number of re-hospitalized patients, defined as a hospital stay >12 hours. | 90 days after discharge. |
| Measure | Description | Time Frame |
|---|---|---|
| Re-hospitalization (infection-related and all-cause) | Report of the total number of re-hospitalized patients, defined as a hospital stay >12 hours. | 30 days after discharge; 180 days after discharge. |
| Mortality (infection-related and all-cause) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Birgitte Lindegaard, MD, PhD | Contact | +4548293874 | birgitte.lindegaard.madsen@regionh.dk | |
| Camilla Koch Ryrsø, MSc, PhD | Contact | +4548293261 | camilla.koch.ryrsoe.01@regionh.dk |
| Name | Affiliation | Role |
|---|---|---|
| Birgitte Lindegaard, MD, PhD | Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital - North Zealand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital | Hillerød | 3400 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Report of the total number.
| 30 days after discharge; 90 days after discharge; 180 days after discharge; 360 days after discharge |
| Handgrip strength | Measure handgrip muscle strength in kilos in the dominant hand using a hand-held dynamometer. The highest number out of three attempts will be recorded. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Lower limb muscle strength and power | Assessment of muscle strength and power of the knee extensor muscles with dynamometry. | Baseline; 1-month after discharge (secondary endpoint), 3-month after discharge (primary endpoint), and 6-month after discharge (secondary endpoint). |
| 30-second sit to stand | A clinical test where the patient performs as many sit-to-stand actions as possible in 30 seconds. Measures leg muscle strength by counting the number of repetitions. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| 1-minute sit to stand | A clinical test where the patient performs as many sit-to-stand actions as possible in 1 minute. Measures endurance by counting the number of repetitions. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| 6-minute walking test | Measure the distance in meters a person can walk in 6 minutes. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Short Physical Performance Battery (SPPB) | An objective measurement instrument combining 3 tests in 1 score. The tests consist of a balance test (measured in seconds), lower extremity strength (measured in seconds), and a walking test measuring functional capacity (measured in seconds). | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Barthel index | Measure of a persons ability to perform activities of daily living. Scores from 0 to 100. The higher the better. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Clinically Frailty Scale | A global clinical measure of the overall frailty of an older person. Scores from 1 to 9. The lower the better. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| EuroQol-5D-5L (EQ-5D-5L) | Measure health-related quality of life divided into the EQ-5D utility index and EQ-VAS score. The Danish EQ-5D-5L utility scores range from -0.757 for state 55555 to 1.0 for state 11111; the higher the score, the better. The EQ VAS is on a 0-100 scale; the higher the score, the better. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| 36-Item Short Form Survey (SF-36) | Measure health-related quality of life. Total score from 0 to 100; the higher the score, the better. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| COPD Assessment Test (CAT) | A patient self-administered questionnaire. An 8-item questionnaire designed to assess the impact of disease on a person's life (health status). Range of CAT scores from 0-40. Higher scores implicates a more severe impact of COPD on a patient's life (total score point). | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Montreal Cognitive Assessment (MoCA) | Measure of mild cognitive impairment. MoCa scores range from 0 to 30. Scores of 26 or over are considered to be normal. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Center for Epidemiologic Studies Depression Scale (CES-D) | A self-report rating scale that is designed to measure current symptoms of depression. Lower score is better. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); 6-month after discharge (secondary endpoint) |
| Family Reported Outcome Measure (FROM-16) | Measure of the impact on the quality of life of an adult family member or partner resulting from having a person (of any age) in a family with any disease or condition, across all of medicine. | 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); 6-month after discharge (secondary endpoint) |
| Physical activity level | The objectivly measured physical activity level assessed with activity trackers. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); 6-month after discharge (secondary endpoint) |
| Blood sample | Concentration of p-phosphate (mmol/l), p-sodium (mmol/l), p-carbamide (mmol/l), and p-potassium (mmol/l). | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of pro- and anti-inflammatory cytokines (IL-6, Il-1ra, IL-18, IL-10, TNF-alpha, etc.) | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of lipids | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of galectin-3 (ng/ml), sST2 (ng/ml), and troponins (ng/ml). | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of NT-proBNP (ng/l). | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Immune function | Complete blood count with differential count. Concentration of immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA), and concentration of subclasses of IgG: IgG1, IgG2, IgG3, and IgG4. | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of HbA1c. | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of c-peptide (pmol/L). | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); 6-month after discharge (secondary endpoint); and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration p-glucose (mmol/L). | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); 6-month after discharge (secondary endpoint); and 12-month after discharge (secondary endpoint). |
| Blood sample | Concentration of p-insulin (pmol/L). | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); 6-month after discharge (secondary endpoint); and 12-month after discharge (secondary endpoint). |
| Biobank blood sample | Whole blood, plasma, and serum. | Baseline; discharge (secondary endpoint); 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), 6-month after discharge (secondary endpoint), and 12-month after discharge (secondary endpoint). |
| Insulin resistance | The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) will be used to measure severity of insulin resistance. Normal reference levels for HOMA-IR is 0.7 to 2.0, with values >2.0 representing clinically significant insulin resistance. | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint), and 6-month after discharge (secondary endpoint). |
| Glycemic variability | Glucose outcomes from the CGM sensor (Dexcom G6) including time in range (TIR) for blood glucose, time above range (TAR) for blood glucose, time below range (TBR) for blood glucose, average blood glucose, and variance in blood glucose (CV). | Baseline (day 0-10); 3-month after discharge (day 80-90, primary endpoint), and 6-month after discharge (day 170-180, secondary endpoint). |
| P-glucose during an oral glucose tolerance test (OGTT) | P-glucose (mmol/L) measured during an OGTT. | Baseline; 3-month after discharge (primary endpoint), and 6-month after discharge (secondary endpoint). |
| P-insulin during an oral glucose tolerance test (OGTT) | P-insulin (pmol/L) measured during an OGTT. | Baseline; 3-month after discharge (primary endpoint), and 6-month after discharge (secondary endpoint). |
| C-peptide during an oral glucose tolerance test (OGTT) | C-peptide (pmol/L) measured during an OGTT. | Baseline; 3-month after discharge (primary endpoint), and 6-month after discharge (secondary endpoint). |
| Insulin sensitivity | Insulin sensitivity using Matsuda index. The index is calculated based on p-glucose and p-insulin in fasting state and during an OGTT. | Baseline; 3 month after discharge (primary endpoint); 6 months after discharge (secondary endpoint). |
| Glucose-lowering medication | Changes in glucose-lowering medication in patients with diabetes | Baseline; 3 months after discharge (primary endpoint); 6 months after discharge (secondary endpoint) |
| Semi-structured qualitative interviews | Semi-structured qualitative interviews with the patient and a relative. The following themes will be explored: perception of the content in the exercise intervention, barriers and enablers towards physical activity, ideas for improvement of the exercise intervention | 1-month after discharge (seconary endpoint), 3-month after discharge (primary endpoint), and 6-month after discharge (secondary endpoint). |
| Adverse events | Numbers of severe adverse events and adverse events | At 1-month after discharge, 3-month after discharge (primary endpoint), and 6-month after discharge. |
| Total and appendicular lean and fat mass | DXA-scan | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Muslce quality and density | Midt-thigh CT-scan | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Fat mass index and fat-free mass index | Bioelectrical impedance analysis | Baseline; 1-month after discharge (secondary endpoint); 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Muscle oxidative stress and inflammation | Muscle biopsies from the m. vastus lateralis of the quadriceps muscle | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Muscle protein synthesis and proteolysis | Muscle biopsies from the m. vastus lateralis of the quadriceps muscle | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Muscle insulin sensitivity | Muscle biopsies from the m. vastus lateralis of the quadriceps muscle | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint). |
| Skeletal muscle cell growth, development, and function | Skeletal muscle cell cultures of muscle tissue from m. vastus lateralis of the quadriceps muscle. | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint) |
| Insulin sensitivity and signaling of adipose tissue | Adipose tissue biopsy | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (secondary endpoint) |
| Adipose tissue inflammation | Adipose tissue biopsy | Baseline; 3-month after discharge (primary endpoint); and 6-month after discharge (seconary endpoint) |
| Adipose tissue immune cell infiltration | Adipose tissue biopsy | Baseline; 3-month after discharg (primary endpoint); and 6-month after discharge (secondary endpoint) |
| Pulmonary medication | Changes in pulmonary medication (tablets and inhalation) | Baseline; 3 months after discharge (primary endpoint); 6 months after discharge (secondary endpoint) |
| Lung function | Spirometry in patients with COPD | Baseline; 3 months after discharge (primary endpoint); 6 months after discharge (secondary endpoint) |
| Lung function | Body plethysmography in patients with COPD | Baseline; 3 months after discharge (primary endpoint); 6 months after discharge (secondary endpoint) |
| Lung function | Single-breath carbon monoxide uptake in patients with COPD | Baseline, 3 months after discharge (primary endpoint); 6 months after discharge (seconary endpoint) |
| Acute exacerbations of COPD | Notification of acute exacerbations of COPD through patient files | Baseline; 3 months after discharge (primary endpoint); 6 months after discharge (secondary endpoint) |
| Health economics | Health costs, the cost per quality-adjusted life years (QALYs), and the lifetime estimated cost per QALY gained will be calculated. | From baseline to 360 days after discharge. |
| Department of Infectious Diseases, Copenhagen University Hospital, Amager-Hvidovre | Hvidovre | 2650 | Denmark |
| Department of Respiratory Medicine, Copenhagen University Hospital, Amager-Hvidovre | Hvidovre | 2650 | Denmark |
| ID | Term |
|---|---|
| D000098968 | Community-Acquired Pneumonia |
| D014552 | Urinary Tract Infections |
| ID | Term |
|---|---|
| D017714 | Community-Acquired Infections |
| D007239 | Infections |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D012140 | Respiratory Tract Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided